Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by StockNews.com to “Hold”

Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

A number of other equities research analysts also recently weighed in on the company. Wells Fargo & Company cut their price target on Ascendis Pharma A/S from $277.00 to $264.00 and set an “overweight” rating for the company in a research note on Wednesday. Evercore ISI raised shares of Ascendis Pharma A/S to a “strong-buy” rating in a research report on Monday, August 26th. Oppenheimer raised shares of Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and set a $180.00 target price for the company in a research report on Thursday. Cantor Fitzgerald cut their price target on shares of Ascendis Pharma A/S from $173.00 to $170.00 and set an “overweight” rating on the stock in a report on Wednesday. Finally, Jefferies Financial Group lifted their price objective on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $187.08.

Ascendis Pharma A/S Trading Up 0.1 %

Shares of NASDAQ:ASND opened at $119.15 on Thursday. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of -12.40 and a beta of 0.63. Ascendis Pharma A/S has a 1 year low of $85.29 and a 1 year high of $161.00. The business has a fifty day simple moving average of $134.38 and a 200 day simple moving average of $138.20.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several hedge funds and other institutional investors have recently made changes to their positions in ASND. Private Ocean LLC bought a new stake in Ascendis Pharma A/S during the 1st quarter valued at approximately $36,000. GAMMA Investing LLC raised its stake in Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 102 shares during the last quarter. Quadrant Capital Group LLC boosted its holdings in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC grew its position in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 91 shares during the last quarter. Finally, Bessemer Group Inc. increased its holdings in shares of Ascendis Pharma A/S by 61.0% during the 1st quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 332 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.